Been looking into weight loss options lately? You've probably come across the word "peptides".
Some are licensed medicines that have transformed how obesity is treated. Others are unlicensed compounds sold on the grey market. And the gap between the two is huge when it comes to safety, legality and whether they actually work.
This guide explains what peptides are, how they support weight loss, which treatments are available in the UK and what you need to know before considering any of them. It also covers the risks of unregulated peptide products sold online, and what genuinely helps alongside licensed treatment.
Peptides sold online as "research chemicals" are not licensed medicines. Do not inject anything that hasn't been prescribed for you.
What is a peptide?
A peptide is a short chain of amino acids, the building blocks of proteins. Your body makes peptides naturally, and uses them as signals that tell cells and organs to do specific jobs. Many hormones, enzymes and nerve messengers are peptides or proteins.
Peptides have attracted so much interest for weight loss because your body already uses them to regulate appetite, blood sugar and metabolism. Researchers have worked out which natural peptides control these processes, and found ways to copy or boost their effects with medicines.
How do peptides support weight loss?
Not all peptides support weight loss, and those that do work in different ways. The most important for weight loss are man-made peptides that mimic gut hormones your body releases after eating.
The two key ones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). They work in overlapping but different ways.
GLP-1 is the better understood of the two. It slows how quickly food leaves your stomach, tells your brain you've eaten, and reduces cravings and the "reward" you get from food. Together, these make it much easier to eat less, without the constant hunger that makes most diets hard to stick to.
GIP's main job is to trigger insulin release when you eat, helping control your blood sugar after meals. Its role in weight loss is less clear-cut and is still being researched.
But targeting both receptors at once appears to lead to more weight loss than GLP-1 alone, which is the idea behind tirzepatide's dual action.
Feeling full sooner is the medicine working. Stop eating when you're satisfied, not when your plate is empty.
These effects don't burn fat directly. They make it easier to eat less, so you take in fewer calories. Many people also notice less "food noise", the constant thoughts about hunger and eating that make dieting so hard.
Clinical trials show that medicines that mimic GLP-1, called GLP-1 receptor agonists, can lead to meaningful weight loss alongside diet and lifestyle changes.
The landmark STEP 1 trial, published in the New England Journal of Medicine in 2021, found that adults taking semaglutide 2.4mg a week alongside lifestyle support lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo.1
Which peptides are available for weight loss in the UK?
Three peptide medicines are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for weight management in adults: semaglutide (Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda).
Not every GLP-1 medicine is a peptide, though. Foundayo (orforglipron) works the same way but isn't a peptide. And some GLP-1 medicines, like Trulicity, are licensed for type 2 diabetes only.
Semaglutide (Wegovy)
Wegovy contains semaglutide, a GLP-1 receptor agonist taken as a weekly injection under the skin. Since June 2026, it's also licensed as a daily tablet.
It's licensed for adults with a BMI of 30 or above, or from 27 with at least one weight-related health condition, such as high blood pressure or type 2 diabetes.2
Semaglutide is also sold as Ozempic, a lower-dose version licensed for type 2 diabetes. Ozempic isn't licensed for weight management and shouldn't be used instead of Wegovy.
Tirzepatide (Mounjaro)
Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP receptors. Targeting both at once tends to lead to more weight loss than GLP-1 alone.
The SURMOUNT-1 trial found that tirzepatide at its highest dose led to an average weight reduction of 20.9% over 72 weeks.3 Like Wegovy, it's a weekly injection and you'll need a clinical consultation to get it.
Liraglutide (Saxenda)
Saxenda was the first GLP-1 receptor agonist licensed for weight management in the UK. It's a daily injection, and has mostly been overtaken by the more effective and convenient weekly options, though it's still an MHRA-licensed treatment.
Orforglipron (Foundayo)
Foundayo contains orforglipron, a once-daily GLP-1 tablet. Unlike the medicines above, orforglipron isn't a peptide. It's a small molecule that works on the same GLP-1 receptor.
The MHRA authorised it on 10 August 2026 for weight management and for blood sugar control in adults with type 2 diabetes, making the UK the first country in Europe to approve it. It isn't yet available to buy through Pharmica.
Dulaglutide (Trulicity)
Trulicity contains dulaglutide, a once-weekly GLP-1 receptor agonist licensed in the UK for type 2 diabetes. It isn't licensed for weight management.
Some weight loss is a recognised side benefit of GLP-1 medicines in people with diabetes. But if weight loss is your main aim, semaglutide and tirzepatide are the licensed options with the stronger evidence.
What unlicensed peptides are being marketed for weight loss?
Alongside licensed medicines, a range of unlicensed peptides are being sold online, often more cheaply and without a prescription. They aren't licensed by the MHRA, and haven't been through the approval process that checks a medicine is safe, good quality and effective.
These products carry serious legal and health risks, and should never be bought or taken. The MHRA has warned about unlicensed weight loss injections sold online, and has taken action against suppliers.
Some of the peptides being marketed for weight loss include:
- Unlicensed semaglutide - sold by some online suppliers as a "research peptide" or "research chemical", often as a powder you mix yourself. These products aren't made to pharmaceutical standards, have no quality control and aren't legally authorised for human use in the UK.
- BPC-157 (Body Protective Compound-157) - a man-made peptide based on a protein found in stomach juices, widely marketed for healing and fat loss. There's no evidence from human trials that it helps with weight loss, and it isn't licensed anywhere in the world as a medicine for people.4
- CJC-1295 and Ipamorelin - peptides that trigger growth hormone release, often sold together with claims about growth hormone and fat loss. The evidence is limited to animal studies and small reports that haven't been peer reviewed. Neither is licensed for human use in the UK.
- Retatrutide - a triple receptor agonist (GLP-1, GIP and glucagon) in late-stage clinical trials. As of 2026, it hasn't been approved by the MHRA or the European Medicines Agency (EMA), but it's already being sold online without legal authorisation.
- CagriSema - a combination of semaglutide and cagrilintide (a type of amylin analogue) developed by Novo Nordisk, in phase 3 trials. It hasn't been submitted to the MHRA for UK approval, but it's already sold by online "research peptide" suppliers, in the same way as unlicensed semaglutide.
- AOD-9604 - a man-made fragment of human growth hormone, studied for its effects on fat metabolism.5 It isn't licensed anywhere as a weight loss treatment.
Why are unlicensed peptides dangerous?
The risks of unregulated peptide products go beyond the lack of evidence. There are several specific concerns:
- Unknown long-term effects - licensed medicines go through years of trials and ongoing safety monitoring once they're on the market. Compounds like BPC-157 and CJC-1295 have no long-term human safety data at all.
- No manufacturing standards - licensed medicines are made under strict Good Manufacturing Practice (GMP) conditions, with independent testing for purity, sterility and dose accuracy. Grey market peptides have none of this. Tests on unlicensed injectable products have found contamination, wrong doses and impurities, including bacterial toxins.
- No dose guidance - licensed treatments start at low doses and go up gradually under clinical supervision. Unlicensed products come with no proper dosing instructions, which makes dangerous over- or under-dosing likely.
- Infection risk from self-injecting - injecting anything carries a risk of infection. That risk is much higher when the product itself may not be sterile.
- Drug interactions - GLP-1 medicines slow how quickly your stomach empties, which affects how other medicines are absorbed. Without a prescriber involved, these interactions can't be managed safely, especially for medicines where small changes in level matter, like blood thinners.
- Heart and metabolism risks - some peptides, especially those that trigger growth hormone release, may affect insulin resistance or heart function in ways that aren't well understood in humans.
Not sure if a seller is legitimate? Check they're registered with the General Pharmaceutical Council before you buy any medicine online.
Side effects of licensed peptides for weight loss
Even with licensed treatments, side effects are common, especially while your dose is going up. The most frequently reported are digestive:
- Nausea - very common (affects more than 1 in 10 people), usually most noticeable after a dose increase
- Vomiting
- Diarrhoea or constipation
- Tummy discomfort or bloating
These usually ease over time as your body adjusts. Most clinical guidance recommends starting at the lowest dose and going up slowly to make them less severe.
Less common but more serious side effects include pancreatitis (inflammation of the pancreas) and gallbladder problems.
Tell your prescriber if you or a family member has had a rare thyroid cancer (medullary thyroid carcinoma) or multiple endocrine neoplasia type 2 (MEN2), so they can take this into account.2
What actually works alongside licensed peptide treatment for weight loss?
Licensed GLP-1 medicines are a tool, not the whole answer. The trials with the biggest weight loss results all combined medicine with structured lifestyle support. Here's what the evidence supports:
- Plenty of protein - GLP-1 medicines reduce your appetite, but they don't change what you eat, only how much. Prioritising protein at each meal helps protect your muscle while you lose weight and helps you feel full.
- Resistance exercise - a big concern with fast weight loss on GLP-1 medicines is losing muscle alongside fat. Resistance training helps protect your muscle and supports your metabolic health during and after treatment.
- Drinking enough - a lower appetite can mean drinking less too. Staying well hydrated supports digestion and helps manage nausea, one of the most common side effects of GLP-1 treatment.
Protein at every meal and two strength sessions a week are the simplest ways to protect your muscle on treatment.
Eating less also means taking in fewer vitamins and minerals. Supplements can help fill some gaps while you're in a calorie deficit:
- Complete multivitamin - a daily multivitamin gives you a nutritional safety net when you're eating much less, covering vitamins A, C, D, the B vitamins, zinc and selenium.
- Omega-3 fatty acids - EPA and DHA contribute to the normal function of the heart (the beneficial effect is obtained with a daily intake of 250mg of EPA and DHA), and DHA contributes to the maintenance of normal brain function (with a daily intake of 250mg of DHA).6 OneVit Omega-3 provides 330mg EPA and 220mg DHA per capsule, sourced from fish oil.
- Vitamin B12 - especially relevant if you follow a plant-based diet, or take metformin alongside GLP-1 medicine for type 2 diabetes, as both can lower your B12 levels. OneVit Vitamin B12 contains B12 as methylcobalamin.
- Vitamin D - vitamin D deficiency is more common in people with obesity, partly because fat tissue holds on to vitamin D and makes less of it available.7 Taking a supplement is advised for most UK adults, and it's especially relevant while you're actively losing weight. Vitamin D contributes to the normal absorption and use of calcium, and vitamin K contributes to the maintenance of normal bones, which is why OneVit pairs them in its D3 and K2 formula.
These supplements don't speed up fat loss on their own. But they help support healthy, sustainable weight management and lower the risk of falling short on nutrients while you're eating less.
When to seek further advice
Contact your GP or prescribing clinician if you:
- Experience severe or persistent nausea, vomiting, or abdominal pain
- Develop symptoms consistent with pancreatitis: severe upper abdominal pain radiating to the back, particularly after eating
- Notice signs of hypoglycaemia (shakiness, sweating, confusion) if you're also taking insulin or sulfonylureas
- Are concerned about rapid muscle loss or persistent fatigue during treatment
- Have purchased or used unlicensed peptide products and are experiencing adverse effects, and seek medical advice without delay
A full list of known side effects and drug interactions is available in the patient information leaflet supplied with your medication.
Frequently asked questions
What are peptides for weight loss?
Peptides for weight loss are short chains of amino acids that influence the body's appetite, blood sugar, and metabolic signalling. In a medical context, the term most commonly refers to GLP-1 receptor agonists - synthetic peptide-based medicines such as semaglutide (Wegovy) and tirzepatide (Mounjaro) that mimic naturally occurring gut hormones to reduce appetite and food intake. The term is also used, more loosely, to describe a range of unlicensed compounds being marketed online, which are a different category entirely and carry significant safety risks.
Are peptides safe for weight loss?
It depends entirely on which peptide you're referring to. Licensed GLP-1 medications such as Wegovy and Mounjaro have been through extensive clinical trials and are approved by the MHRA for use in adults with obesity. They're prescribed and monitored by clinicians, with a well-understood side effect profile. Unlicensed peptides sold online - including compounds such as BPC-157, CJC-1295, and unregulated semaglutide - have no pharmaceutical-grade quality control, no clinically validated dosing guidance, and in many cases no human safety data at all. These are not safe for weight loss use.
Do peptides work for weight loss?
Licensed GLP-1 peptide medications have strong clinical evidence behind them. The STEP 1 trial found semaglutide 2.4mg produced an average weight loss of 14.9% over 68 weeks, and the SURMOUNT-1 trial found tirzepatide produced up to 20.9% at its highest dose. These are among the most effective non-surgical weight loss interventions currently available. Unlicensed peptide compounds marketed for weight loss lack comparable human evidence - claims made for products such as BPC-157 or AOD-9604 are not supported by clinical trial data.
How do peptides work for weight loss?
Licensed weight loss peptides work by mimicking gut hormones that your body naturally releases after eating. GLP-1 receptor agonists slow gastric emptying (so you feel full for longer), signal to the brain that you've eaten, and reduce the reward response to food - effectively lowering appetite and reducing what's often described as "food noise." Tirzepatide additionally targets GIP receptors, which play a role in insulin regulation and appear to enhance the overall weight loss effect. None of these mechanisms burn fat directly; they work by making it easier to sustain a caloric deficit.
Where can I buy peptides for weight loss in the UK?
Licensed peptide-based weight loss medicines - Wegovy and Mounjaro - are available in the UK through regulated online pharmacies and GP services following a clinical consultation. They require a valid prescription and cannot legally be sold without one. Pharmica offers online consultations for both treatments with discreet delivery. Unlicensed peptide compounds sold on websites without a prescription are not authorised for human use in the UK and should not be purchased.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Novo Nordisk Ltd. Wegovy (semaglutide) 2.4mg Summary of Product Characteristics. Electronic Medicines Compendium (eMC). medicines.org.uk/emc
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design. 2011;17(16):1612-1632. PMID:21548867
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Endocrinology. 2001;142(12):5182-9. PMID:11713213
- European Food Safety Authority (EFSA). Scientific Opinion on the substantiation of health claims related to EPA, DHA, and maintenance of normal cardiac function. EFSA Journal. 2010;8(10):1796. doi:10.2903/j.efsa.2010.1796
- Vimaleswaran KS, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomisation analysis of multiple cohorts. PLOS Medicine. 2013;10(2):e1001383. doi:10.1371/journal.pmed.1001383
This article is intended for informational purposes only and does not replace professional medical advice. Always read the patient information leaflet supplied with your medication and speak to a healthcare professional if you have specific concerns.